- Home
- VTGN vs AEON Comparison
VTGN vs AEON Comparison
Compare VTGN & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | AEON |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 25.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTGN | AEON |
|---|---|---|
| Price | $0.63 | $0.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $7.20 |
| AVG Volume (30 Days) | ★ 619.3K | 127.2K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.43 |
| 52 Week High | $5.14 | $1.45 |
Technical Indicators
Market Signals| Indicator | VTGN | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 39.69 |
| Support Level | $0.56 | $0.68 |
| Resistance Level | $0.66 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 79.11 | 23.93 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.